Cambridge biotech startup seeking to repurpose Vioxx raises $5M
Tremeau Pharmaceuticals, a Cambridge biotech startup that is seeking to repurpose the controversial Merck& Co. arthritis drug Vioxx as a treatment for joint pain caused by hemophilia, has closed its first equity round.
Tremeau, which was founded last year, announced Thursday that it has raised $5.2 million in equity financing, although it did not disclose the investors that participated. The six-employee company said the funding would be used to advance the drug — whose generic name is rofecoxib…
Source: bizjournals.com Health Care:Pharmaceuticals headlines - Category: Pharmaceuticals Authors: Max Stendahl Source Type: news
More News: Arthritis | Biotechnology | Funding | Haemophilia | Health Management | Hemophilia | Merck | Pain | Pharmaceuticals | Rheumatology | Vioxx